Company intelligence / Profile preview

PanFlu

Ownership: Private
Development stage: Other

Overview

PanFlu is a biotechnology company focused on the development of next-generation vaccines for seasonal and pandemic influenza. The company utilizes a proprietary live attenuated influenza vaccine (LAIV) platform designed to provide broader and more durable protection compared to traditional inactivated vaccines. By targeting conserved regions of the influenza virus, PanFlu aims to create 'universal' vaccine candidates that can mitigate the threat of emerging avian flu strains and seasonal drift. Their approach emphasizes rapid scalability and ease of administration to address global public health needs during outbreaks.

Therapeutic areas: Infectious Diseases
Modalities: VaccineLive attenuated virus
Industry: Biotech

Beyond the preview

Go deeper on PanFlu.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PanFlu.

Explore the full profile